Benzinga's Top Initiations

By: Benzinga
Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX ) with a “buy” rating. The target price for Mast Therapeutics is set to $3. Mast Therapeutics' shares closed at $0.45 yesterday. Bank of America initiated coverage on shares of NPS Pharmaceuticals (NASDAQ: NPSP )
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.